The purpose of this study is to evaluate the effects of pyridostigmine (Mestinon) on patient vocal outcomes after undergoing laryngeal botulinum neurotoxin (BoNT) injections, which is a standard treatment for spasmodic dysphonia. Pyridostigmine (Mestinon) has been used for treatment of BoNT overdose, and it is our hope that it will be beneficial in the management of post BoNT breathy phase.
Age range
21 Years – 100 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Rainbow Passage Reading Pre- and Post-Pyridostigmine (Mestinon)
Timeframe: 15 Minutes
CAPE-V Pre- and Post-Pyridostigmine (Mestinon)
Timeframe: 15 Minutes
Glottal Function Index Pre- and Post-Pyridostigmine (Mestinon)
Timeframe: 15 Minutes
Adapted Borg Scale Pre- and Post-Pyridostigmine (Mestinon)
Timeframe: 15 Minutes